The use of chemoimmunotherapy in the first-line treatment of advanced small cell lung cancer: a case report and brief literature review

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Background: Small cell lung cancer (SCLC) is a malignancy with an aggressive course and an extremely poor prognosis. In its advanced form, median survival rarely exceeds 12 months, even with chemotherapy. However, in recent years, the advent of immune checkpoint inhibitors (PD-L1 inhibitors), such as atezolizumab, has improved survival rates while maintaining acceptable toxicity.

Description of the clinical case: This case report presents the experience of treating a patient with disseminated small cell lung cancer. She achieved a significant positive response to combination chemoimmunotherapy (etoposide + carboplatin + atezolizumab) followed by maintenance therapy with an anti-PDL1 inhibitor. A brief overview of clinical trials on the efficacy of PD-L1 blockers in the treatment of SCLC is also provided.

Conclusion: The combination of immunotherapy and chemotherapy has become the standard of care for small cell lung carcinoma. The high efficacy of this combination was demonstrated in our clinical case.

About the authors

Zaina M. Yusupova

Pirogov Russian National Research Medical University (Pirogov University)

Email: golubev194@gmail.com
ORCID iD: 0009-0000-1328-766X

Student, Faculty of General Medicine

 

Russian Federation, Moscow

Maryana B. Muradova

Pirogov Russian National Research Medical University (Pirogov University)

Email: golubev194@gmail.com
ORCID iD: 0009-0001-0512-7006

Student, Faculty of General Medicine

Russian Federation, Moscow

Alina M. Zakharova

Pirogov Russian National Research Medical University (Pirogov University)

Email: golubev194@gmail.com
ORCID iD: 0009-0001-8273-5582

Student, Faculty of General Medicine

Russian Federation, Moscow

Pavel V. Golubev

A.F. Tsyb Medical Radiological Research Center, Branch of the National Medical Research Radiological Center

Author for correspondence.
Email: golubev194@gmail.com
ORCID iD: 0000-0003-3532-6476

Cand. Sci. (Med.), Oncologist, Department of Antitumor Drug Therapy, A.F. Tsyb Medical Radiological Research Center, Branch of the National Medical Research Radiological Center, Obninsk, Russia; golubev194@gmail.com,

Russian Federation, Obninsk

Evgeniya S. Kuzmina

Yudin City Clinical Hospital

Email: golubev194@gmail.com
ORCID iD: 0009-0007-2856-5176

Cand. Sci. (Med.), Head of the Chemotherapy Department No. 2, Oncology Center No. 1

Russian Federation, Moscow

Vladislav M. Kuzmin

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: golubev194@gmail.com
ORCID iD: 0009-0000-9658-3586

Student

Russian Federation, Moscow

Abidat K. Kachmasova

Yudin City Clinical Hospital

Email: golubev194@gmail.com
ORCID iD: 0009-0005-2365-495X

Oncologist, Chemotherapy Department No. 2, Oncology Center No. 1

Russian Federation, Moscow

Svetlana P. Viderker

Yudin City Clinical Hospital

Email: golubev194@gmail.com
ORCID iD: 0009-0003-1025-4784

Oncologist, Chemotherapy Department No. 2, Oncology Center No. 1

Russian Federation, Moscow

References

  1. Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834
  2. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна и др. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с. [Malignant neoplasms in Russia in 2023 (incidence and mortality). Ed. by A.D. Kaprin et al. Moscow: P.A. Herzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, 2024, 276 p. (In Russ.)].
  3. Состояние онкологической помощи населению России в 2024 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025. илл. 275 с.
  4. Rudin C.M., Brambilla E., Faivre-Finn C., Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. https://dx.doi.org/10.1038/s41572-020-00235-0
  5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 1.2026.
  6. Liu S.V., Reck M., Mansfield A.S., et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–630. https://dx.doi.org/10.1200/JCO.20.01055
  7. Reck M., Mok T.S.K., Nishio M., et al.; IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. https://dx.doi.org/10.1016/S2213-2600(19)30084-0
  8. Ai L., Chen J., Yan H., He Q., Luo P., Xu Z., Yang X. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Des Devel Ther. 2020 Sep 8;14:3625-3649. https://dx.doi.org/10.2147/DDDT.S267433
  9. Stephen V. Liu et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). JCO. 2021;39:619–630. https://dx.doi.org/10.1200/JCO.20.01055.
  10. Wang S., Li Y., Liu Z., et al. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis. Lung Cancer. 2023;178:47–56. https://dx.doi.org/10.1016/j.lungcan.2023.02.003
  11. Horn L., Mansfield A.S., Szczęsna A., et al.; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220–2229. https://dx.doi.org/10.1056/NEJMoa1809064
  12. Goldman J.W., Dvorkin M., Chen Y., et al.; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65. https://dx.doi.org/10.1016/S1470-2045(20)30539-8
  13. Paz-Ares L. et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(Issue 10212):1929–1939.
  14. Rudin C.M., Awad M.M., Navarro A., et al.; KEYNOTE-604 Investigators. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38(21):2369–2379. https://dx.doi.org/10.1200/JCO.20.00793
  15. Kim H.R., Awad M.M., Navarro A., et al. Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC. JTO Clin Res Rep. 2023;4(11):100572. https://dx.doi.org/10.1016/j.jtocrr.2023.100572
  16. Cheng Y., Han L., Wu L., et al.; ASTRUM-005 Study Group. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022 Sep 27;328(12):1223–1232. doi: 10.1001/jama.2022.16464
  17. Li C., Lei S., Li D., et al. Global burden and trends of lung cancer incidence and mortality. Chinese Medical J. 2023;136(13):1583–1590. https://dx.doi.org/10.1097/CM9.0000000000002529

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).